Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

nt; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, VALSTAR(R) and SUPPRELIN(R)-LA; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, DELATESTRYL and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/30/2014)... This report analyzes the worldwide markets for Enteral Feeding Devices ... Pumps, Nasogastric Tubes, and Others. The report provides ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. The report profiles 38 ...
(Date:9/30/2014)... BEDFORD, Mass. , Sept. 30, 2014  Hologic, ... Stephen MacMillan , Hologic,s President and Chief Executive ... Bell Ceremony on October 1, the first day of ... will discuss the Company,s campaign focused on the important ... system approved by the FDA as clinically superior to ...
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... natural way to modernize medicine, announced today the ... line of nutraceuticals developed to address men and ... staying healthy and vibrant into old age while ... line includes three condition-specific, whole-food and herb-based formulas, ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
... Therapy Services Holdings, Inc. ("Radiation Therapy Services" or the "Company") ... Wells Fargo Securities 2011 Healthcare Conference on Wednesday, June 22, ... held at the Intercontinental Hotel in Boston, MA. ... available by visiting the Events section of the Company,s Web ...
... ERT ), announced today that Keith ... present at the 2011 Wells Fargo Securities Healthcare ... in Boston. Interested parties may access ... at  http://www.ert.com . The webcast may also be ...
Cached Medicine Technology:ERT to Present at the 2011 Wells Fargo Securities Healthcare Conference on June 23, 2011 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
(Date:10/1/2014)... has shown that more than 80 per cent of ... The study found that medicines called ,JAK inhibitors, halted ... that is present in more than 80 per cent ... or are in clinical trials, for diseases including rheumatoid ... cancer is the second-most common cancer in Australia with ...
(Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
(Date:10/1/2014)... Hills, CA (PRWEB) October 01, 2014 ... internationally-franchised Fit Body Boot Camp fitness boot camps, he’s ... selling personal training , with sold out business summits, ... stint as marketing consultant to a recent Spike TV ... Keuilian says that now is the time for personal ...
(Date:10/1/2014)... October 01, 2014 Farmington Company ... a redefined mission and visual identity helping brokers, ... partnering with them to create greater benefit communication ... that focuses on empowering customers to better leverage ... The crown jewel of the rebrand is the ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2
... Feb. 15 that a 70 % minimum requirement in the ... for admission to medical// and dental colleges in the open ... % of the weightage for admission in medical and dental ... common entrance test (CET), the government said it would be ...
... and sound health info Kerala and Goa have lifted the ... revealed by Minister for Medical Education and Animal Husbandry V.S. ... that this indicates that the situation is under control. ... make policies Chief Minister H.D. Kumaraswamy said the Government has ...
... charge contraceptives have a VAT of 17.5% on them. This ... in the ensuing budget.,Gordon Brown is due to present the ... Street chemist Superdrug which said that it was confident of ... said the move followed a successful 10-month campaign. ...
... Researchers from Texas A&M University said that poorly maintained ... breeding grounds for potentially lethal bacterial strains. They tested ... some kind of microbial growth.// ,Various Bacterial ... of the samples, while 81% had fungi and 34% ...
... Indian mind trainer and motivator has been helping South Africans ... subconscious mind. ,Jeetendra Adhia's workshops in various cities seek to ... the mind which he says lies between the conscious state ... never utilised more than 10 percent of their mind power," ...
... Researchers have developed a molecular map and other similar ... found in the Asian population//. ,'The inroads ... more effectively,' said Professor Soo Khee Chee, director of ... led by the NCC included experts from the University ...
Cached Medicine News:
Suture Cutters, Straight...
Suture scissor...
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
Medicine Products: